MLTX — MoonLake Immunotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.45bn
- $1.92bn
- 38
- 32
- 49
- 34
Annual cashflow statement for MoonLake Immunotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -53.6 | -64.5 | -44.1 |
| Depreciation | |||
| Non-Cash Items | 14 | 10 | 7.51 |
| Other Non-Cash Items | |||
| Changes in Working Capital | 4.48 | -1.43 | -6.22 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -35.2 | -55.9 | -42.8 |
| Capital Expenditures | -0.051 | -0.016 | -0.285 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | — | -32.3 | -24.9 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -0.051 | -32.3 | -25.2 |
| Financing Cash Flow Items | — | 135 | -2.75 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 43.3 | 120 | 480 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 8.04 | 31.5 | 412 |